About Us
Clinical Trial
- About the Study
- Am I Eligible?
Pipeline
Partnering
Investors
News
- Latest News
- Publications
Contact Us

About Us
Clinical Trial
- About the Study
- Am I Eligible?
Pipeline
Partnering
Investors
News
- Latest News
- Publications
Contact Us

Home Investors Stock Information

Stock Information

Stock Information

Stock Information

Stock Information

Stock Information

Stock Information

Stock Information

Stock Information

Stock Information

Stock Information

Real Time Quote

SUBSCRIBE

Get email notifications of the latest Ampio news.

Latest News

Ampio Suspends Patient Enrollment in its Phase 3 Study of Ampion for Severe Osteoarthritis of the Knee and Explores Other Options to Complete Trial

Ampio is Preparing an Expanded Access FDA protocol to Study Nebulized Ampion as a Treatment for Moderate to Severe Acute Respiratory Distress Syndrome Associated with COVID-19

Ampio Provides Corporate Update

February 21, 2020

© 2020 Ampio Pharmaceuticals Inc.

373 Inverness Parkway, Suite 200
Englewood, CO 80112 USA

Main office: +1 720 437 6500
Fax: +1 720 437 6501

General email inquiries: info@ampiopharma.com

Home
About Us
Clinical Trial
Pipeline
Partnering
Investors
News
Contact Us